• Latest
  • Trending

Protalix Biotherapeutics Hosts Key Opinion Leader Webinar on Fabry Disease and PRX-102

04.12.2022

BioArctic: Lecanemab Receives Priority Review Status in Japan

30.01.2023

2023 NFL draft order, team needs: Bengals and 49ers last to lock draft positions ahead of Super Bowl

30.01.2023
Alka Yagnik is the most listened to singer in the world;  beats Taylor Swift, Beyonce

Alka Yagnik is the most listened to singer in the world; beats Taylor Swift, Beyonce

30.01.2023
How Descendants 3 Honored Cameron Boyce After His Death

How Descendants 3 Honored Cameron Boyce After His Death

30.01.2023
Adani hits back at Hindenburg, says he made all the disclosures – Reuters

Adani hits back at Hindenburg, says he made all the disclosures – Reuters

30.01.2023
Live Stock Market Updates: Stocks to Watch Today – Zee News

Live Stock Market Updates: Stocks to Watch Today – Zee News

30.01.2023

How to Access and Use the Privacy Dashboard on Your Android…

30.01.2023
Preview: Inter Milan vs Atalanta BC – prediction, team news, rosters – Sports Mole

Preview: Inter Milan vs Atalanta BC – prediction, team news, rosters – Sports Mole

30.01.2023

Injured Patrick Mahomes joins list of NFL’s bravest playoff performers, including Tom Brady, Terrell Owens

30.01.2023
Rita Ora stays comfortable in an oversized coat on a flight from JFK airport in New York

Rita Ora stays comfortable in an oversized coat on a flight from JFK airport in New York

30.01.2023

BOOK TODAY: SOUTHWEST AIRLINES ADDS MORE FLIGHTS FOR THE BIG GAME

30.01.2023

Cowboys OC Kellen Moore out as head coach Mike McCarthy takes charge of Dallas play calls

30.01.2023
Monday, January 30, 2023
  • World
  • Economics
  • Sport
    • Basketball
    • Football
    • Nfl
    • Golf
    • F1
    • UFC
  • Technology
  • Culture
    • Arts
  • Media
    • Film
    • Celebs
    • TV
  • LifeStyle
    • Auto
  • Travel
OLTNEWS
  • World
  • Economics
  • Sport
    • Basketball
    • Football
    • Nfl
    • Golf
    • F1
    • UFC
  • Technology
  • Culture
    • Arts
  • Media
    • Film
    • Celebs
    • TV
  • LifeStyle
    • Auto
  • Travel
OLTNEWS
No Result
View All Result

Home » Technology » Protalix Biotherapeutics Hosts Key Opinion Leader Webinar on Fabry Disease and PRX-102

Protalix Biotherapeutics Hosts Key Opinion Leader Webinar on Fabry Disease and PRX-102

04/12/2022 14:31:15
in Technology
0
0
SHARES
Share on WhatsappShare on Facebook

Related posts

BioArctic: Lecanemab Receives Priority Review Status in Japan

30.01.2023

How to Access and Use the Privacy Dashboard on Your Android…

30.01.2023

Webcast to be held on Monday, December 5e at 8:30 a.m. EST

CARMIEL, Israel, December 4, 2022 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant protein therapeutics produced by its owner ProCellEx® plant cell-based protein expression system, announced today that the company will host a key opinion leader (KOL) webinar on Fabry disease and PRX-102 (pegunigalsidase alfa) on Monday, December 5, 2022 at 8:30 a.m. Eastern Standard Time (EST).

The KOL Event webinar will feature Myrl D. HolidaPA-C, University of Iowa Stead Family Children’s Hospital, which will discuss the robust PRX-102 clinical program for the potential treatment of patients with Fabry disease. A live Q&A session will follow the formal presentations.

Myrl D. Holida is a medical assistant with 35 years of patient care experience, initially treating pediatric bone marrow transplant (BMT) patients with end-stage malignancies and patients with lysosomal storage disorders as part of a clinical test. Myrl’s experience includes many levels of research, from the cardiovascular animal laboratory to the clinical trial investigator for lysosomal storage disorders. He was involved in the original enzyme replacement trials for Fabry disease in the late 90s and early 2000s and was a principal investigator for the co-administration of oral chaperone therapy with agalsidase beta and migalastat, and for agalsidase alpha and velaglucerase “rescue therapy” during enzyme shortages beginning in 2009. Myrl brought initial Phase I PRX-102 trials of Protalix to his facility and recruited almost half of the United States patients with agalsidase beta in Protalix’s Phase III BRIGHT rollover clinical trial, which evaluated dosing every 4 weeks. His institution is a major Fabry Treatment Center, recently recognized as a Center of Excellence by the National Organization for Rare Disorders (NORD), thanks in part to his efforts over the years. He has treated patients with Adrenoleukodystrophy, Metachromatic Leukodystrophy, MPS I, MPS II, MPS III, MPS IV, MPS VI, Gaucher Disease, Lysosomal Acid Lipase Deficiency (LALD), Pompe disease and multiple hematological disorders. Myrl is also actively involved in a Fabry gene therapy trial and manages three generations of Fabry patients.

Webinar details

The webinar will be available via the following link: https://lifescievents.com/event/protalix-biotherapeutics-kol-event-on-fabry-disease-prx-102-pegunigalsidase-alfa/.

Please access the webinar at least 15 minutes before the KOL event to register, download and install any necessary audio software. The webinar will be available for replay for two weeks at the link above.

About Protalix BioTherapeutics, Inc.

Protalix is ​​a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed by its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain US Food and Drug Administration (FDA) approval for a protein produced by a plant cell-based suspension expression system. Protalix’s unique expression system represents a novel method for developing recombinant proteins on an industrial scale.

ProCellEx’s first Protalix product, taliglucerase alfa, was approved by the FDA in May 2012 and subsequently by regulatory authorities in other countries. Protalix has licensed worldwide rights to develop and commercialize taliglucerase alfa to Pfizer Inc., excluding Brazilwhere Protalix retains all rights.

Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of recombinant human α-galactosidase-A protein for the treatment Fabry’s disease; alidornase alfa or PRX-110, for the treatment of various human respiratory diseases or conditions; PRX-115, a recombinant PEGylated uricase expressed in plant cells for the treatment of severe gout; PRX-119, a long-acting plant cell-expressed DNase I for the treatment of NET-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici SpA, both in United States and outside United Statesfor the development and commercialization of pegunigalsidase alfa.

Forward-looking statements

To the extent that statements contained in this press release are not strictly historical, all such statements are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms “expect” , “anticipate”, “believe”, “estimate”, “project”, “may”, “plan”, “will”, “would”, “should”, and “intend”, and other words or expressions of similar significance are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Such statements are based on our current beliefs and expectations about those future outcomes.Drug discovery and development involves a high degree of risk and the end results of a clinical trial may be e different from the preliminary results of the clinical trial. Factors that could cause material differences are described in our filings with the United States Securities and Exchange Commission. The statements contained in this press release speak only as of the date hereof and we undertake no obligation to update this information, except as required by law. The statements contained in this press release speak only as of the date hereof and we undertake no obligation to update this information, except as required by law.

Contact Investor
Chuck PadalaGeneral director
LifeSci Advisors
646-627-8390
[email protected]

SOURCEProtalix BioTherapeutics, Inc.

Related

Previous Post

Missouri Basketball Preview: SEMO comes to town as the last mid-major on the schedule – Rock M Nation

Next Post

Bowl projections: Ohio State in college football playoffs after USC fall as Georgia, Michigan and TCU clinches – Reuters

Related Posts

Technology

BioArctic: Lecanemab Receives Priority Review Status in Japan

30.01.2023
0

STOCKHOLM, January 30, 2023 /PRNewswire/ -- BioArctic AB's (ad) (NASDAQ Stockholm: BIOA B) partner Eisai today announced that the application...

Read more

How to Access and Use the Privacy Dashboard on Your Android…

30.01.2023

BOOK TODAY: SOUTHWEST AIRLINES ADDS MORE FLIGHTS FOR THE BIG GAME

30.01.2023

BioArctic: Lecanemab Receives Priority Review Status in Japan

30.01.2023

Intella X, Neowiz Web3 and software

30.01.2023

Ivirizu Sehuencas hydropower plant built by POWERCHINA wins good reputation

30.01.2023
Load More
Next Post
Bowl projections: Ohio State in college football playoffs after USC fall as Georgia, Michigan and TCU clinches – Reuters

Bowl projections: Ohio State in college football playoffs after USC fall as Georgia, Michigan and TCU clinches - Reuters

Recent Posts

  • BioArctic: Lecanemab Receives Priority Review Status in Japan
  • 2023 NFL draft order, team needs: Bengals and 49ers last to lock draft positions ahead of Super Bowl
  • Alka Yagnik is the most listened to singer in the world; beats Taylor Swift, Beyonce
  • How Descendants 3 Honored Cameron Boyce After His Death
  • Adani hits back at Hindenburg, says he made all the disclosures – Reuters

Archives

  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • EN

© 2020

No Result
View All Result
  • World
  • Economics
  • Sport
    • Basketball
    • Football
    • Nfl
    • Golf
    • F1
    • UFC
  • Technology
  • Culture
    • Arts
  • Media
    • Film
    • Celebs
    • TV
  • LifeStyle
    • Auto
  • Travel

© 2020

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.